If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about spectacle and more about structure. The industry moved away from broad promises of transformation and toward the less glamorous work of trial design, regulatory discipline, safety, and scalability. That shift did not weaken the field. It clarified it.
